{
    "nctId": "NCT00971945",
    "briefTitle": "Rollover Study of Weekly Paclitaxel (BMS-181339) in Patients With Advanced Breast Cancer",
    "officialTitle": "Rollover Study of Weekly Paclitaxel (BMS-181339) in Patients With Advanced Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 6,
    "primaryOutcomeMeasure": "Number of Participants Experiencing Adverse Events",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Subjects who were confirmed to have a response after receiving at least two courses of weekly paclitaxel therapy and considered to need to continue the therapy by the investigator/subinvestigator among the patients with advanced or recurrent breast cancer who had met the selection criteria and participated in the preceding phase II clinical study",
    "sex": "FEMALE",
    "minimumAge": "N/A",
    "stdAges": "CHILD, ADULT, OLDER_ADULT"
}